Skip to main content
S&P 5007,720.39-0.30%DOW52,342.56-0.25%NASDAQ26,184.72-1.38%BTC$77,045.00-4.95%ETH$2,215.83-5.85%GOLD$4,026.60-0.12%OIL$102.79+0.77%
Smart Investors Daily
SID Premium
Ocular Therapeutix, Inc. logo

NASDAQ · OCUL

Ocular Therapeutix, Inc.

Healthcare · Biotechnology

$7.31

Up+$0.02 (+0.27%)

Updated Oct 30, 2026, 8:50 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.55B
P/E ratio
-10.81
Dividend yield
0.00%
52-week range
$6.00 – $16.44
Volume
2.21M
Avg. volume
3.15M

Price performance · OCUL

OCUL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

OCUL closed at $7.31 after 21 trading sessions, up 0.27% for the selected period.

Last close
$7.31
Period change
+0.27%
Period low
$6.29
Period high
$7.56
Daily close
View OHLC price history
OCUL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$7.36$7.535$7.29$7.312.21M
Oct 28, 2026$6.68$7.34$6.60$7.292.85M
Oct 27, 2026$6.48$6.75$6.42$6.722.22M
Oct 26, 2026$6.50$6.62$6.40$6.471.69M
Oct 23, 2026$6.68$6.68$6.345$6.501.86M
Oct 22, 2026$6.42$6.665$6.395$6.612.15M
Oct 21, 2026$6.69$6.7499$6.375$6.482.49M
Oct 20, 2026$6.30$6.775$6.30$6.652.62M
Oct 19, 2026$7.13$7.18$6.00$6.298.36M
Oct 16, 2026$7.38$7.39$6.85$6.872.76M
Oct 15, 2026$7.29$7.465$7.23$7.383.25M
Oct 14, 2026$7.14$7.30$7.07$7.202.21M
Oct 13, 2026$7.55$7.61$7.20$7.243.22M
Oct 12, 2026$7.60$7.75$7.36$7.563.67M
Oct 9, 2026$7.49$7.68$7.38$7.542.63M
Oct 8, 2026$7.20$7.565$7.06$7.513.9M
Oct 7, 2026$7.26$7.545$7.19$7.232.93M
Oct 6, 2026$7.30$7.565$7.13$7.342.81M
Oct 5, 2026$6.93$7.27$6.79$7.255.62M
Oct 2, 2026$7.40$7.425$6.935$6.964.96M
Oct 1, 2026$7.63$7.705$7.26$7.294.51M

Latest OCUL news

The latest Smart Investors Daily articles mentioning OCUL.

Stock researchCompany · Overview

OCUL research

Overview

Company profile and research snapshot.

Company profile

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$26.25
Implied upside
—
Analysts
—
OCUL recent ratings
DateFirmRatingTarget
Oct 19, 2026NeedhamBuy—
Oct 12, 2026UBSBuy—
Oct 2, 2026Chardan CapitalBuy—
Sep 29, 2026NeedhamBuy—
Sep 16, 2026Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jul 24, 2026

Is Ocular Therapeutix (OCUL) Still Undervalued Or Is AXPAXLI Hope Already Priced In?

Ocular Therapeutix (OCUL) has drawn investor attention after recent trading saw the stock close at $8.62, with returns under pressure over the past month and past 3 months despite positive annual revenue growth. See our latest analysis for Ocular Therapeutix. Over a longer horizon, Ocular Therapeutix’s share price has come under pressure, with the year to date share price return down 27.07%, while the 3 year total shareholder return is up 100%. This points to strong historical swings in...

Yahoo · Jul 23, 2026

Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment

Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman, President and CEO Dr. Pravin Dugel described as alignment with the U.S. Food and Drug Administration on

Yahoo · Jul 21, 2026

3 Cash-Burning Stocks with Open Questions

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By